PDEX
Price
$62.38
Change
+$1.82 (+3.01%)
Updated
Oct 22 closing price
Capitalization
199.82M
7 days until earnings call
Intraday BUY SELL Signals
ZBH
Price
$98.84
Change
+$3.98 (+4.20%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
18.09B
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PDEX vs ZBH

PDEX vs ZBH Comparison Chart in %
View a ticker or compare two or three
VS
PDEX vs. ZBH commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PDEX is a StrongBuy and ZBH is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for PDEX with price predictions
Oct 22, 2026

PDEX's RSI Indicator recovers from oversold territory

The RSI Oscillator for PDEX moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 28 of the 31 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 60 cases where PDEX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on PDEX as a result. In 81 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

Following a +5.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDEX advanced for three days, in 242 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

PDEX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for PDEX turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 35 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

PDEX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PDEX crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDEX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. PDEX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.195) is normal, around the industry mean (4.961). P/E Ratio (14.712) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (0.400) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.061) is also within normal values, averaging (56.876).

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

A.I.Advisor
a Summary for ZBH with price predictions
Oct 22, 2026

ZBH in upward trend: price rose above 50-day moving average on October 22, 2026

ZBH moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 70%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on ZBH as a result. In 56 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.

The Moving Average Convergence Divergence (MACD) for ZBH just turned positive on October 12, 2026. Looking at past instances where ZBH's MACD turned positive, the stock continued to rise in 29 of 45 cases over the following month. The odds of a continued upward trend are 64%.

Following a +1.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZBH advanced for three days, in 195 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 10-day moving average for ZBH crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZBH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

ZBH broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ZBH entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ZBH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.433) is normal, around the industry mean (2.874). P/E Ratio (23.024) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.576) is also within normal values, averaging (11.052). Dividend Yield (0.010) settles around the average of (0.009) among similar stocks. P/S Ratio (2.233) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZBH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

FUNDAMENTALS RATINGS
PDEX vs ZBH: Fundamental Ratings
PDEX
ZBH
OUTLOOK RATING
1..100
5415
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
54100
SMR RATING
1..100
3180
PRICE GROWTH RATING
1..100
4049
P/E GROWTH RATING
1..100
951
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDEX's Valuation (57) in the Medical Or Nursing Services industry is in the same range as ZBH (68) in the Medical Specialties industry. This means that PDEX’s stock grew similarly to ZBH’s over the last 12 months.

PDEX's Profit vs Risk Rating (54) in the Medical Or Nursing Services industry is somewhat better than the same rating for ZBH (100) in the Medical Specialties industry. This means that PDEX’s stock grew somewhat faster than ZBH’s over the last 12 months.

PDEX's SMR Rating (31) in the Medical Or Nursing Services industry is somewhat better than the same rating for ZBH (80) in the Medical Specialties industry. This means that PDEX’s stock grew somewhat faster than ZBH’s over the last 12 months.

PDEX's Price Growth Rating (40) in the Medical Or Nursing Services industry is in the same range as ZBH (49) in the Medical Specialties industry. This means that PDEX’s stock grew similarly to ZBH’s over the last 12 months.

PDEX's P/E Growth Rating (9) in the Medical Or Nursing Services industry is somewhat better than the same rating for ZBH (51) in the Medical Specialties industry. This means that PDEX’s stock grew somewhat faster than ZBH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PDEXZBH
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
61%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
56%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
65%
MACD
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
64%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
62%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 1 day ago
57%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 3 days ago
67%
Declines
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 9 days ago
56%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
70%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
54%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (PDEX: $60.56 vs. ZBH: $98.81)
Brand notoriety: PDEX and ZBH are both not notable
PDEX represents the Pharmaceuticals: Other, while ZBH is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: PDEX: 29% vs. ZBH: 84%
Market capitalization -- PDEX: $199.82M vs. ZBH: $18.09B
PDEX [@Pharmaceuticals: Other] is valued at $199.82M. ZBH’s [@Medical/Nursing Services] market capitalization is $18.09B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $156.8B. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $173.92B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.3B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.7B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PDEX’s FA Score shows that 2 FA rating(s) are green while ZBH’s FA Score has 0 green FA rating(s).

  • PDEX’s FA Score: 2 green, 3 red.
  • ZBH’s FA Score: 0 green, 5 red.
According to our system of comparison, PDEX is a better buy in the long-term than ZBH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PDEX’s TA Score shows that 4 TA indicator(s) are bullish while ZBH’s TA Score has 4 bullish TA indicator(s).

  • PDEX’s TA Score: 4 bullish, 5 bearish.
  • ZBH’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, PDEX is a better buy in the short-term than ZBH.

Price Growth

PDEX (@Pharmaceuticals: Other) experienced а +1.24% price change this week, while ZBH (@Medical/Nursing Services) price change was +4.69% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.

Reported Earning Dates

PDEX is expected to report earnings on Oct 29, 2026.

ZBH is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (+0.74% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical/Nursing Services (-1.50% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
PDEX
Daily Signal:
Gain/Loss:
ZBH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

PDEX and

Correlation & Price change

A.I.dvisor tells us that PDEX and TCMD have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PDEX and TCMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDEX
1D Price
Change %
PDEX100%
+3.01%
TCMD - PDEX
24%
Poorly correlated
+1.12%
PRE - PDEX
23%
Poorly correlated
-0.96%
WAT - PDEX
23%
Poorly correlated
-0.41%
GKOS - PDEX
23%
Poorly correlated
-0.09%
ZBH - PDEX
22%
Poorly correlated
+4.16%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VTEC96.280.75
+0.79%
Vanguard California Tax-Exempt Bond ETF (VTEC)
VBCF73.210.55
+0.76%
Vanguard Target Maturity 2032 Corporate Bond ETF (VBCF)
RPAR21.660.07
+0.31%
RPAR Risk Parity ETF (RPAR)
XLBI23.510.06
+0.26%
State Street Materials Select Sector SPDR Premium Income ETF (XLBI)
GIND23.50-0.03
-0.13%
Goldman Sachs India Equity ETF (GIND)